HDAC9 and urinary bladder carcinoma: HDAC inhibitors, e.g., SAHA for cutaneous T-lymphocyte tumors, Mocetinostat for bladder cancer, and Panobinostat for multiple myeloma, were approved by the U.S. FDA [14, 15].